Clinical trialNATerminated
CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer
Evaluation of CT Perfusion Parameters as a Potential Biomarker for Treatment Response in Pancreatic Cancer
- Outcome
- Stopped earlyTermination due to slow accrual (Enrollment)
- Phase
- NA
- Status
- Terminated
- Study type
- Interventional
- Start
- 22 June 2017
- Expected end
- 1 June 2022
- Enrollment
- 70 participants
- Sites
- 1
- Primary outcomes
- Correlation between pre-treatment computed tomography (CT) tumor perfusion parameters and percentage of patients who achieve curative (R0) surgical resection after neoadjuvant chemotherapy; Correlation between pre-treatment CT tumor perfusion parameters and tumor response after treatment; Correlation of pre-treatment CT tumor perfusion parameters with overall survival; Correlation of pre-treatment CT tumor perfusion parameters with overall survival; Correlation of pre-treatment CT tumor perfusion parameters with progression free survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 6 July 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This pilot clinical trial studies how well computed tomography (CT) perfusion images work in assessing treatment response in patients with pancreatic cancer. Analyzing specific measurements on the CT perfusion images may help doctors better determine how a tumor responds to chemotherapy and/or radiation therapy and may help guide treatment for patients with pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
OUTLINE: Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery. After completion of the study, patients are followed up periodically for 2 years.